Company / SG&A Expense
Day One Biopharmaceuticals, Inc. SG&A Expense History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$120.6M
FY2025
5-year range
$29.2M / $120.6M
FY2021-FY2025
Trend
+4.4%
vs FY2024
Sector context
#101 of 211
Health Care
What the data says
At $121M, Day One Biopharmaceuticals, Inc.'s sg&a expense ranks #111 of 211 in the Health Care sector. SG&A Expense has increased for 6 consecutive years, from $1M in FY2019 to $121M in FY2025.
Based on SEC 10-K filings.
$121M in FY2025 with a 5-year CAGR of +91.5%.
Increased from $76M to $121M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +25.3%
- 5-Year CAGR
- +91.5%
- 10-Year CAGR
- -
Sector benchmark
#111 of 211 in Health CareTop 52% of 211This company $120.6M Sector average $728.7M
▼
-83.5% below sector average
Key checks
Key Insights
- Day One Biopharmaceuticals, Inc.'s sg&a expense has grown for 6 consecutive years.
- 5-year CAGR of +91.5%, indicating consistent growth.
- In FY2025, sg&a expense increased 4.4% year-over-year.
- Ranks #101 out of 211 companies in the Health Care sector.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $120.6M | +4.4% |
| FY2024 | $115.5M | +52.8% |
| FY2023 | $75.5M | +23.3% |
| FY2022 | $61.3M | +110.2% |
| FY2021 | $29.2M | +522.8% |
| FY2020 | $4.7M | +365.4% |
| FY2019 | $1.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026